# The Effect of BIA 2-093 on the Steady-state Pharmacodynamic and Pharmacokinetic Profiles of Warfarin

> **NCT02287415** · PHASE1 · COMPLETED · sponsor: **Bial - Portela C S.A.** · enrollment: 13 (actual)

## Conditions studied

- Epilepsy

## Interventions

- **DRUG:** BIA 2-093
- **DRUG:** Warfarin

## Key facts

- **NCT ID:** NCT02287415
- **Lead sponsor:** Bial - Portela C S.A.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2002-05
- **Primary completion:** 2002-07
- **Final completion:** 2002-07
- **Target enrollment:** 13 (ACTUAL)
- **Last updated:** 2014-12-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02287415

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02287415, "The Effect of BIA 2-093 on the Steady-state Pharmacodynamic and Pharmacokinetic Profiles of Warfarin". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT02287415. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*